Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast CancerEttl J.
Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
Dr. med. Johannes Ettl
Frauenklinik und Poliklinik, Klinikum Rechts der Isar
Technische Universität München
Ismaningerstrasse 22, 81675 Munich, Germany
Do you have an account?
Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed.
© 2016 S. Karger GmbH, Freiburg
- Turner NC, Ro J, Andre F, et al.: Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209-219.
Fry DW, Harvey PJ, Keller PR, et al.: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-1438.
- Caldon CE, Daly RJ, Sutherland RL, et al.: Cell cycle control in breast cancer cells. J Cell Biochem 2006;97:261-274.
- Finn RS, Dering J, Conklin D, et al.: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
- Flaherty KT, Lorusso PM, Demichele A, et al.: Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18:568-576.
- Finn RS, Crown JP, Lang I, et al.: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35.
Finn RS, Crown JP, Lang I, et al.: The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2- metastatic breast cancer (MBC): subanalysis from a randomized phase II study. J Clin Oncol 2015;33(suppl):abstr 572.
Crown JP, Finn RS, Ettl J, et al.: Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: a subgroup analysis by age of the PALOMA-1/TRIO-18 trial. J Clin Oncol 2015;33(suppl):abstr 571.
Finn RS, Crown JP, Ettl J, et al.: Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): a subgroup analysis of PALOMA-1/TRIO-18. J Clin Oncol 2015;33(suppl):abstr 575.
- Thomssen C, Augustin D, Ettl J, et al.: ABC3 Consensus: assessment by a German group of experts. Breast Care (Basel) 2016;11:61-70.
- Harbeck N, Iyer S, Turner N, et al.: Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 2016;27:1047-1054.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.